✉  info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Remdesivir (COVID 19) Market Research Report Information By Dosage (5mg, 10mg, 50mg, 100mg), Distribution Channel (Hospitals, Drug Stores, others) and By Region (North America, Europe, Asia-Pacific, and Rest of the World) –Market Forecast Till 2032


ID: MRFR/HC/8663-HCR | 101 Pages | Author: Rahul Gotadki| December 2024

Market Segmentation


Remdesivir (COVID 19) Dosage Outlook (USD Billion, 2018-2032)




  • 5mg




  • 10mg




  • 50mg




  • 100mg




Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




  • Hospitals




  • Drug stores




  • Others




Remdesivir (COVID 19) Regional Outlook (USD Billion, 2018-2032)




  • North America Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others






    • US Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others






    • Canada Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others








  • Europe Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others






    • Germany Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others






    • France Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others






    • UK Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others






    • Italy Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others






    • Spain Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others






    • Rest Of Europe Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others








  • Asia-Pacific Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others






    • China Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others






    • Japan Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others






    • India Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others






    • Australia Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others






    • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others








  • Rest of the World Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others






    • Middle East Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others






    • Africa Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others






    • Latin America Outlook (USD Billion, 2018-2032)




    • Remdesivir (COVID 19) by Dosage




      • 5mg




      • 10mg




      • 50mg




      • 100mg






    • Remdesivir (COVID 19) Distribution channel Outlook (USD Billion, 2018-2032)




      • Hospitals




      • Drug stores




      • Others







Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

Table of Contents

1. EXECUTIVE SUMMARY

1.1. Market Attractiveness Analysis

1.1.1. Global Remdesivir (COVID-19) Market, Dosage

1.1.2. Global Remdesivir (COVID-19) Market, Distribution Channel

1.1.3. Global Remdesivir (COVID-19) Market, by Region

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.3. Market Structure

2.4. Assumptions & Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Techniques

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.2.1. Increasing prevalence of Covid-19

4.2.2. Rising geriatric population

4.2.3. XXXXX

4.3. Restraints

4.4. Opportunities

4.4.1. XXX

5. MARKET FACTOR ANALYSIS

5.1. Supply Chain Analysis

5.1.1. R&D and Designing

5.1.2. Manufacturing

5.1.3. Distribution & Sales

5.1.4. Post Sales Services

5.2. Porter’s Five Forces Model

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. Clinical Trials

6. GLOBAL REMDESIVIR (COVID-19) MARKET, BY DOSAGE

6.1. Overview

6.2. 5mg

6.3. 10mg

6.4. 50mg

6.5. 100mg

7. GLOBAL REMDESIVIR (COVID-19) MARKET, BY DISTRIBUTION CHANNEL

7.1. Overview

7.2. Hospitals

7.3. Drug Stores

7.4. Others

8. GLOBAL REMDESIVIR (COVID-19) MARKET, BY REGION

8.1. Overview

8.2. Americas

8.2.1. Market Estimates & Forecast, by Dosage, 2022–2030

8.2.2. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.2.3. Market Estimates & Forecast, by Region, 2022–2030

8.2.3.1. North America

8.2.3.1.1. Market Estimates & Forecast, by Dosage, 2022–2030

8.2.3.1.2. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.2.3.1.3. Market Estimates & Forecast, by Country, 2022–2030

8.2.3.1.3.1. US

8.2.3.1.3.1.1. Market Estimates & Forecast, by Dosage, 2022–2030

8.2.3.1.3.1.2. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.2.3.1.3.2. Canada

8.2.3.1.3.2.1. Market Estimates & Forecast, by Dosage, 2022–2030

8.2.3.1.3.2.2. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.2.3.2. Latin America

8.2.3.2.1. Market Estimates & Forecast, by Dosage, 2022–2030

8.2.3.2.2. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.3. Europe

8.3.1. Market Estimates & Forecast, by Dosage, 2022–2030

8.3.2. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.3.3. Market Estimates & Forecast, by Region, 2022–2030

8.3.3.1. Western Europe

8.3.3.1.1. Market Estimates & Forecast, by Dosage, 2022–2030

8.3.3.1.2. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.3.3.1.3. Market Estimates & Forecast, by Country, 2022–2030

8.3.3.1.3.1. Germany

8.3.3.1.4. Market Estimates & Forecast, by Dosage, 2022–2030

8.3.3.1.5. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.3.3.1.5.1. France

8.3.3.1.6. Market Estimates & Forecast, by Dosage, 2022–2030

8.3.3.1.7. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.3.3.1.7.1. UK

8.3.3.1.8. Market Estimates & Forecast, by Dosage, 2022–2030

8.3.3.1.9. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.3.3.1.9.1. Italy

8.3.3.1.10. Market Estimates & Forecast, by Dosage, 2022–2030

8.3.3.1.11. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.3.3.1.11.1. Spain

8.3.3.1.12. Market Estimates & Forecast, by Dosage, 2022–2030

8.3.3.1.13. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.3.3.1.13.1. Rest of Western Europe

8.3.3.1.14. Market Estimates & Forecast, by Product, 2022–2030

8.3.3.1.15. Market Estimates & Forecast, by Dosage, 2022–2030

8.3.3.1.16. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.3.4. Eastern Europe

8.3.4.1.1. Market Estimates & Forecast, by Dosage, 2022–2030

8.3.4.1.2. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.4. Asia-Pacific

8.4.1. Market Estimates & Forecast, by Dosage, 2022–2030

8.4.2. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.4.3. Market Estimates & Forecast, by Country, 2022–2030

8.4.3.1. China

8.4.3.1.1. Market Estimates & Forecast, by Dosage, 2022–2030

8.4.3.1.2. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.4.3.2. India

8.4.3.2.1. Market Estimates & Forecast, by Dosage, 2022–2030

8.4.3.2.2. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.4.3.3. Japan

8.4.3.3.1. Market Estimates & Forecast, by Dosage, 2022–2030

8.4.3.3.2. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.4.3.4. Australia

8.4.3.4.1. Market Estimates & Forecast, by Dosage, 2022–2030

8.4.3.4.2. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.4.3.5. South Korea

8.4.3.5.1. Market Estimates & Forecast, by Dosage, 2022–2030

8.4.3.5.2. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.4.3.6. Rest of Asia-Pacific

8.4.3.6.1. Market Estimates & Forecast, by Dosage, 2022–2030

8.4.3.6.2. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.5. Middle East & Africa

8.5.1. Market Estimates & Forecast, by Dosage, 2022–2030

8.5.2. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.5.3. Market Estimates & Forecast, by Region, 2022–2030

8.5.3.1. Middle East

8.5.3.1.1. Market Estimates & Forecast, by Dosage, 2022–2030

8.5.3.1.2. Market Estimates & Forecast, by Distributional Channel, 2022–2030

8.5.3.2. Africa

8.5.3.2.1. Market Estimates & Forecast, by Dosage, 2022–2030

8.5.3.2.2. Market Estimates & Forecast, by Distributional Channel, 2022–2030

9. COMPETITIVE LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the global Remdesivir (COVID-19) market

9.5. Competitive Benchmarking

9.6. Leading Player in terms of Number of developments in global Remdesivir (COVID-19) market

9.7. Key Developments & Growth Strategies

9.7.1. New Product Launch

9.7.2. Merger & Acquisition

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix & Market Ratio

9.8.1. Sales & Operating Income 2019

9.8.2. Major Players R&D Expenditure 2019

10. COMPANY PROFILES

10.1. Gilead Sciences, Inc.

10.1.1. Company Overview

10.1.2. Financial Overview

10.1.3. Products Offered

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Mylan

10.3. Cipla

10.4. Hetero Labs

10.5. Jubilant Life Sciences

10.6. Others

11. APPENDIX

11.1. References

11.2. Related Reports

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
Press Release
Category icon
Remdesivir (COVID 19) Market: High Demand for Remdesivir Drugs due to the outbreak of COVID-19 Gl...
Logo
Dmca Cloudflare ssl
Paypal footer Ssl
Services Industry Expertise Consulting Services Articles How To Order FAQs
Our Company About US Careers Contact Us Terms & Conditions Privacy Policy
Banking Partners
Amex Mastercard1
Razerpay
Hdfcbank
Visa
✉  info@marketresearchfuture.com
📞  +1 (855) 661-4441(US)
📞  +44 1720 412 167(UK)

© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)